Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTVMM513)

• DOT Name: Albumin (ALB)
• Gene Name: ALB
• Related Disease:
  Congenital analbuminemia
  Hyperthyroxinemia, familial dysalbuminemic
• UniProt ID: ALBU_HUMAN
• PDB ID: 1AO6 ; 1BJ5 ; 1BKE ; 1BM0 ; 1E78 ; 1E7A ; 1E7B ; 1E7C ; 1E7E ; 1E7F ; 1E7G ; 1E7H ; 1E7I ; 1GNI ; 1GNJ ; 1H9Z ; 1HA2 ; 1HK1 ; 1HK2 ; 1HK3 ; 1HK4 ; 1HK5 ; 1N5U ; 1O9X ; 1TF0 ; 1UOR ; 1YSX ; 2BX8 ; 2BXA ; 2BXB ; 2BXC ; 2BXD ; 2BXE ; 2BXF ; 2BXG ; 2BXH ; 2BXI ; 2BXK ; 2BXL ; 2BXM ; 2BXN ; 2BXO ; 2BXP ; 2BXQ ; 2ESG ; 2I2Z ; 2I30 ; 2N0X ; 2VDB ; 2VUE ; 2VUF ; 2XSI ; 2XVQ ; 2XVU ; 2XVV ; 2XVW ; 2XW0 ; 2XW1 ; 2YDF ; 3A73 ; 3B9L ; 3B9M ; 3CX9 ; 3JQZ ; 3JRY ; 3LU6 ; 3LU7 ; 3LU8 ; 3SQJ ; 3TDL ; 3UIV ; 4BKE ; 4E99 ; 4EMX ; 4G03 ; 4G04 ; 4HGK ; 4HGM ; 4IW1 ; 4IW2 ; 4K2C ; 4K71 ; 4L8U ; 4L9K ; 4L9Q ; 4LA0 ; 4LB2 ; 4LB9 ; 4N0F ; 4N0U ; 4S1Y ; 4Z69 ; 5FUO ; 5GIX ; 5GIY ; 5ID7 ; 5IFO ; 5IJF ; 5UJB ; 5VNW ; 5X52 ; 5YB1 ; 5YOQ ; 5Z0B ; 6A7P ; 6EZQ ; 6HSC ; 6JE7 ; 6L4K ; 6M4R ; 6M58 ; 6M5D ; 6M5E ; 6QIO ; 6QIP ; 6R7S ; 6WUW ; 6XV0 ; 6YG9 ; 6ZL1 ; 7A9C ; 7AAE ; 7AAI ; 7D6J ; 7DJN ; 7DL4 ; 7EEK ; 7FFR ; 7FFS ; 7JWN ; 7OV1 ; 7OV5 ; 7OV6 ; 7QFE ; 7VR0 ; 7VR9 ; 7WKZ ; 7WLF ; 7WOJ ; 7WOK ; 7WZ9 ; 7X7X ; 7Y2D ; 7Z57 ; 8A9Q ; 8CKS ; 8EW4 ; 8EW7 ; 8EY5 ; 8H0O ; 8Q3F
• Pfam ID: PF00273
• Sequence:
  MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF
  EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP
  ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
  FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV
  ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK
  ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR
  RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE
  QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV
  LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL
  SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV
  AASQAALGL
• Function: Binds water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs (Probable). Its main function is the regulation of the colloidal osmotic pressure of blood (Probable). Major zinc transporter in plasma, typically binds about 80% of all plasma zinc. Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma. Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner. The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood. The rank order of affinity is zinc > calcium > magnesium. Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli. Does not prevent iron uptake by the bacterial siderophore aerobactin.
• Tissue Specificity: Plasma.
• KEGG Pathway: Thyroid hormone synthesis (hsa04918)
• Reactome Pathway:
  Recycling of bile acids and salts (R-HSA-159418)
  Heme biosynthesis (R-HSA-189451)
  Heme degradation (R-HSA-189483)
  Scavenging of heme from plasma (R-HSA-2168880)
  Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) (R-HSA-381426)
  Post-translational protein phosphorylation (R-HSA-8957275)
  HDL remodeling (R-HSA-8964058)
  Cytoprotection by HMOX1 (R-HSA-9707564)
  Aspirin ADME (R-HSA-9749641)
  Prednisone ADME (R-HSA-9757110)
  Ciprofloxacin ADME (R-HSA-9793528)
  Platelet degranulation (R-HSA-114608)

Molecular Interaction Atlas (MIA) of This DOT

2 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Congenital analbuminemia	DISE3DNQ	Definitive	Autosomal recessive	[1]
Hyperthyroxinemia, familial dysalbuminemic	DIS0BPAW	Strong	Autosomal dominant	[2]

This DOT Affected the Regulation of Drug Effects of 2 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
Hydrogen peroxide	DM1NG5W	Approved	Albumin (ALB) increases the abundance of Hydrogen peroxide.	[78]
3R14S-OCHRATOXIN A	DM2KEW6	Investigative	Albumin (ALB) decreases the transport of 3R14S-OCHRATOXIN A.	[84]

This DOT Affected the Drug Response of 14 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
Folic acid	DMEMBJC	Approved	Albumin (ALB) affects the binding of Folic acid.	[79]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Approved	Albumin (ALB) affects the binding of Eicosapentaenoic acid/docosa-hexaenoic acid.	[76]
Aluminium	DM6ECN9	Approved	Albumin (ALB) affects the binding of Aluminium.	[80]
Sulfamethoxazole	DMB08GE	Approved	Albumin (ALB) increases the Agranulocytosis ADR of Sulfamethoxazole.	[81]
Tanespimycin	DMNLQHK	Phase 2	Albumin (ALB) affects the binding of Tanespimycin.	[82]
Benoxaprofen	DM5ZOX8	Withdrawn from market	Albumin (ALB) decreases the response to substance of Benoxaprofen.	[83]
Hexadecanoic acid	DMWUXDZ	Investigative	Albumin (ALB) affects the binding of Hexadecanoic acid.	[76]
Bilirubin	DMI0V4O	Investigative	Albumin (ALB) affects the binding of Bilirubin.	[85]
Paraoxon	DMN4ZKC	Investigative	Albumin (ALB) decreases the response to substance of Paraoxon.	[86]
Benzoquinone	DMNBA0G	Investigative	Albumin (ALB) affects the binding of Benzoquinone.	[87]
Chlorphrifos oxon	DMGBT68	Investigative	Albumin (ALB) decreases the response to substance of Chlorphrifos oxon.	[86]
Icosapentum	DMF1CM7	Investigative	Albumin (ALB) affects the binding of Icosapentum.	[76]
MYRISTIC ACID	DMYX0BL	Investigative	Albumin (ALB) affects the binding of MYRISTIC ACID.	[76]
bromocresol green	DMXTVZ8	Investigative	Albumin (ALB) affects the binding of bromocresol green.	[88]

4 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate decreases the methylation of Albumin (ALB).	[3]
Olanzapine	DMPFN6Y	Approved	Olanzapine affects the phosphorylation of Albumin (ALB).	[31]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene decreases the methylation of Albumin (ALB).	[68]
methylglyoxal	DMRC3OZ	Investigative	methylglyoxal increases the oxidation of Albumin (ALB).	[76]

27 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Ciclosporin	DMAZJFX	Approved	Ciclosporin decreases the expression of Albumin (ALB).	[4]
Tretinoin	DM49DUI	Approved	Tretinoin decreases the expression of Albumin (ALB).	[5]
Acetaminophen	DMUIE76	Approved	Acetaminophen decreases the expression of Albumin (ALB).	[6]
Doxorubicin	DMVP5YE	Approved	Doxorubicin decreases the expression of Albumin (ALB).	[7]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of Albumin (ALB).	[9]
Vorinostat	DMWMPD4	Approved	Vorinostat increases the expression of Albumin (ALB).	[11]
Zoledronate	DMIXC7G	Approved	Zoledronate increases the expression of Albumin (ALB).	[13]
Menadione	DMSJDTY	Approved	Menadione affects the expression of Albumin (ALB).	[14]
Dexamethasone	DMMWZET	Approved	Dexamethasone decreases the expression of Albumin (ALB).	[15]
Troglitazone	DM3VFPD	Approved	Troglitazone decreases the expression of Albumin (ALB).	[16]
Irinotecan	DMP6SC2	Approved	Irinotecan decreases the expression of Albumin (ALB).	[18]
Diclofenac	DMPIHLS	Approved	Diclofenac increases the expression of Albumin (ALB).	[19]
Azacitidine	DMTA5OE	Approved	Azacitidine increases the expression of Albumin (ALB).	[21]
Obeticholic acid	DM3Q1SM	Approved	Obeticholic acid decreases the expression of Albumin (ALB).	[22]
Capsaicin	DMGMF6V	Approved	Capsaicin increases the expression of Albumin (ALB).	[24]
Colchicine	DM2POTE	Approved	Colchicine affects the expression of Albumin (ALB).	[26]
Prednisolone	DMQ8FR2	Approved	Prednisolone increases the expression of Albumin (ALB).	[27]
Methimazole	DM25FL8	Approved	Methimazole decreases the expression of Albumin (ALB).	[35]
Clofibrate	DMPC1J7	Approved	Clofibrate increases the expression of Albumin (ALB).	[36]
Alfacalcidol	DM1237M	Phase 4	Alfacalcidol increases the expression of Albumin (ALB).	[59]
SNDX-275	DMH7W9X	Phase 3	SNDX-275 increases the expression of Albumin (ALB).	[11]
Telmisartan	DMS3GX2	Phase 3 Trial	Telmisartan affects the expression of Albumin (ALB).	[63]
Amiodarone	DMUTEX3	Phase 2/3 Trial	Amiodarone increases the expression of Albumin (ALB).	[64]
phorbol 12-myristate 13-acetate	DMJWD62	Phase 2	phorbol 12-myristate 13-acetate decreases the expression of Albumin (ALB).	[67]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A affects the expression of Albumin (ALB).	[70]
Trichostatin A	DM9C8NX	Investigative	Trichostatin A increases the expression of Albumin (ALB).	[11]
Butanoic acid	DMTAJP7	Investigative	Butanoic acid increases the expression of Albumin (ALB).	[11]

67 Drug(s) Affected the Protein Interaction/Cellular Processes of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Cisplatin	DMRHGI9	Approved	Cisplatin affects the binding of Albumin (ALB).	[8]
Quercetin	DM3NC4M	Approved	Quercetin affects the binding of Albumin (ALB).	[10]
Methotrexate	DM2TEOL	Approved	Methotrexate decreases the secretion of Albumin (ALB).	[12]
Aspirin	DM672AH	Approved	Aspirin decreases the secretion of Albumin (ALB).	[17]
Clozapine	DMFC71L	Approved	Clozapine affects the binding of Albumin (ALB).	[20]
Zidovudine	DM4KI7O	Approved	Zidovudine affects the binding of Albumin (ALB).	[23]
Liothyronine	DM6IR3P	Approved	Liothyronine affects the binding of Albumin (ALB).	[25]
Sertraline	DM0FB1J	Approved	Sertraline affects the binding of Albumin (ALB).	[28]
Ritonavir	DMU764S	Approved	Ritonavir affects the binding of Albumin (ALB).	[23]
Dihydroartemisinin	DMBXVMZ	Approved	Dihydroartemisinin affects the binding of Albumin (ALB).	[29]
Cholecalciferol	DMGU74E	Approved	Cholecalciferol affects the binding of Albumin (ALB).	[30]
Vitamin A	DMJ2AH4	Approved	Vitamin A affects the binding of Albumin (ALB).	[32]
Isoniazid	DM5JVS3	Approved	Isoniazid affects the binding of Albumin (ALB).	[33]
Warfarin	DMJYCVW	Approved	Warfarin affects the binding of Albumin (ALB).	[34]
Atazanavir	DMSYRBX	Approved	Atazanavir affects the binding of Albumin (ALB).	[23]
Nevirapine	DM6HX9B	Approved	Nevirapine affects the binding of Albumin (ALB).	[23]
Imipramine	DM2NUH3	Approved	Imipramine affects the binding of Albumin (ALB).	[37]
Nelfinavir mesylate	DMFX6G8	Approved	Nelfinavir mesylate affects the binding of Albumin (ALB).	[23]
Efavirenz	DMC0GSJ	Approved	Efavirenz affects the binding of Albumin (ALB).	[23]
Flurbiprofen	DMGN4BY	Approved	Flurbiprofen affects the binding of Albumin (ALB).	[38]
Mefenamic acid	DMK7HFI	Approved	Mefenamic acid affects the binding of Albumin (ALB).	[39]
Naproxen	DMZ5RGV	Approved	Naproxen affects the binding of Albumin (ALB).	[40]
Amsacrine	DMZKYIV	Approved	Amsacrine affects the binding of Albumin (ALB).	[41]
Abacavir	DMMN36E	Approved	Abacavir affects the binding of Albumin (ALB).	[23]
Flucloxacillin	DMNUWST	Approved	Flucloxacillin affects the binding of Albumin (ALB).	[42]
Diazepam	DM08E9O	Approved	Diazepam affects the binding of Albumin (ALB).	[34]
Ketoprofen	DMRKXPT	Approved	Ketoprofen affects the binding of Albumin (ALB).	[43]
Polyethylene glycol	DM4I1JP	Approved	Polyethylene glycol increases the secretion of Albumin (ALB).	[44]
Zalcitabine	DMH7MUV	Approved	Zalcitabine affects the binding of Albumin (ALB).	[23]
Ibrutinib	DMHZCPO	Approved	Ibrutinib affects the binding of Albumin (ALB).	[45]
Furosemide	DMMQ8ZG	Approved	Furosemide affects the binding of Albumin (ALB).	[46]
Stavudine	DM6DEK9	Approved	Stavudine affects the binding of Albumin (ALB).	[23]
Lamivudine	DMI347A	Approved	Lamivudine affects the binding of Albumin (ALB).	[23]
Valsartan	DMREUQ6	Approved	Valsartan decreases the export of Albumin (ALB).	[47]
Glibenclamide	DM8JXPZ	Approved	Glibenclamide affects the binding of Albumin (ALB).	[48]
Hydralazine	DMU8JGH	Approved	Hydralazine affects the binding of Albumin (ALB).	[49]
Urea	DMUK75B	Approved	Urea decreases the folding of Albumin (ALB).	[50]
Isoflurophate	DMBSK7X	Approved	Isoflurophate affects the binding of Albumin (ALB).	[51]
Tolbutamide	DM02AWV	Approved	Tolbutamide affects the binding of Albumin (ALB).	[43]
Fenoprofen	DML5VQ0	Approved	Fenoprofen affects the binding of Albumin (ALB).	[43]
Saquinavir	DMG814N	Approved	Saquinavir affects the binding of Albumin (ALB).	[23]
Didanosine	DMI2QPE	Approved	Didanosine affects the binding of Albumin (ALB).	[23]
Dicumarol	DMFQCB1	Approved	Dicumarol affects the binding of Albumin (ALB).	[52]
Quinolones	DM5GVHU	Approved	Quinolones affects the binding of Albumin (ALB).	[53]
Halothane	DM80OZ5	Approved	Halothane affects the binding of Albumin (ALB).	[54]
Ziprasidone	DMM58JY	Approved	Ziprasidone affects the binding of Albumin (ALB).	[20]
Emtricitabine	DMBMUWZ	Approved	Emtricitabine affects the binding of Albumin (ALB).	[23]
Tolmetin	DMWUIJE	Approved	Tolmetin affects the binding of Albumin (ALB).	[55]
Acetohexamide	DMR6N7H	Approved	Acetohexamide affects the binding of Albumin (ALB).	[56]
Echothiophate Iodide	DMSNVGB	Approved	Echothiophate Iodide affects the binding of Albumin (ALB).	[51]
Meprednisone	DMTL9IP	Approved	Meprednisone affects the binding of Albumin (ALB).	[57]
Exenatide	DMYHBKN	Approved	Exenatide affects the binding of Albumin (ALB).	[58]
Camptothecin	DM6CHNJ	Phase 3	Camptothecin affects the binding of Albumin (ALB).	[60]
Rigosertib	DMOSTXF	Phase 3	Rigosertib affects the binding of Albumin (ALB).	[61]
Guaiacol	DMN4E7T	Phase 3	Guaiacol affects the binding of Albumin (ALB).	[62]
Phenol	DM1QSM3	Phase 2/3	Phenol affects the binding of Albumin (ALB).	[62]
QLT-091001	DMZI4OV	Phase 2/3	QLT-091001 affects the binding of Albumin (ALB).	[65]
XR-5000	DMOKUA5	Phase 2	XR-5000 affects the binding of Albumin (ALB).	[41]
Zomepirac	DM7APNJ	Withdrawn from market	Zomepirac affects the binding of Albumin (ALB).	[69]
Glyphosate	DM0AFY7	Investigative	Glyphosate affects the binding of Albumin (ALB).	[71]
D-glucose	DMMG2TO	Investigative	D-glucose decreases the uptake of Albumin (ALB).	[72]
2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE	DMNQL17	Investigative	2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE affects the binding of Albumin (ALB).	[73]
ELLAGIC ACID	DMX8BS5	Investigative	ELLAGIC ACID affects the binding of Albumin (ALB).	[74]
Oleic acid	DM54O1Z	Investigative	Oleic acid decreases the secretion of Albumin (ALB).	[75]
	DM9CEI5		affects the binding of Albumin (ALB).	[58]
Protoporphyrin IX	DMWYE7A	Investigative	Protoporphyrin IX affects the binding of Albumin (ALB).	[34]
MANGIFERIN	DMWAF5Z	Investigative	MANGIFERIN affects the binding of Albumin (ALB).	[77]

2 Drug(s) Affected the Biochemical Pathways of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
DNCB	DMDTVYC	Phase 2	DNCB increases the metabolism of Albumin (ALB).	[66]
cinnamaldehyde	DMZDUXG	Investigative	cinnamaldehyde increases the metabolism of Albumin (ALB).	[66]

References

• [1] Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
• [2] Familial dysalbuminaemic hyperthyroxinaemia: a rapid and novel mass spectrometry approach to diagnosis. Ann Clin Biochem. 2016 Jul;53(Pt 4):504-7. doi: 10.1177/0004563215598168. Epub 2015 Jul 13.
• [3] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [4] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [5] All-trans retinoic acid down-regulates human albumin gene expression through the induction of C/EBPbeta-LIP. Biochem J. 2006 Jul 15;397(2):345-53. doi: 10.1042/BJ20051863.
• [6] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [7] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [8] The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy. Int J Oncol. 2006 Jul;29(1):261-8.
• [9] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [10] Covalent binding of the flavonoid quercetin to human serum albumin. J Agric Food Chem. 2005 May 18;53(10):4194-7. doi: 10.1021/jf050061m.
• [11] Histone deacetylase inhibitor valproic acid promotes the differentiation of human induced pluripotent stem cells into hepatocyte-like cells. PLoS One. 2014 Aug 1;9(8):e104010.
• [12] Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues. Toxicol Sci. 2016 Dec;154(2):354-367. doi: 10.1093/toxsci/kfw169. Epub 2016 Sep 7.
• [13] Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan;92(1):469-485.
• [14] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [15] Effects of inhaled beclomethasone compared to systemic dexamethasone on lung inflammation in preterm infants at risk of chronic lung disease. Pediatr Pulmonol. 1999 Jun;27(6):383-7. doi: 10.1002/(sici)1099-0496(199906)27:6<383::aid-ppul4>3.0.co;2-v.
• [16] Multiparametric assay using HepaRG cells for predicting drug-induced liver injury. Toxicol Lett. 2015 Jul 2;236(1):16-24. doi: 10.1016/j.toxlet.2015.04.014. Epub 2015 Apr 28.
• [17] Moderation of the platelet releasate response by aspirin. Blood. 2007 Jun 1;109(11):4786-92. doi: 10.1182/blood-2006-07-038539. Epub 2007 Feb 15.
• [18] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [19] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [20] Opposite clozapine and ziprasidone effects on the reactivity of plasma albumin SH-group are the consequence of their different binding properties dependent on protein fatty acids content. Chem Biol Interact. 2019 Sep 25;311:108787. doi: 10.1016/j.cbi.2019.108787. Epub 2019 Aug 7.
• [21] Self-assembled 3D spheroids and hollow-fibre bioreactors improve MSC-derived hepatocyte-like cell maturation in vitro. Arch Toxicol. 2017 Apr;91(4):1815-1832.
• [22] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [23] Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. doi: 10.1080/15216540400016286.
• [24] A comparative proteomic analysis for capsaicin-induced apoptosis between human hepatocarcinoma (HepG2) and human neuroblastoma (SK-N-SH) cells. Proteomics. 2008 Nov;8(22):4748-67. doi: 10.1002/pmic.200800094.
• [25] In vitro fluorescence displacement investigation of thyroxine transport disruption by bisphenol A. J Environ Sci (China). 2011;23(2):315-21. doi: 10.1016/s1001-0742(10)60408-1.
• [26] [Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):207-12.
• [27] Prednisolone can increase glomerular permeability to proteins in nephrotic syndrome. Kidney Int. 1988 Jun;33(6):1169-74. doi: 10.1038/ki.1988.126.
• [28] Exploring binding properties of sertraline with human serum albumin: Combination of spectroscopic and molecular modeling studies. Chem Biol Interact. 2015 Dec 5;242:235-46. doi: 10.1016/j.cbi.2015.10.006. Epub 2015 Oct 22.
• [29] Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells. Chem Res Toxicol. 2015 Oct 19;28(10):1903-13. doi: 10.1021/acs.chemrestox.5b00105. Epub 2015 Sep 21.
• [30] Increased circulating levels of vitamin D binding protein in MS patients. Toxins (Basel). 2015 Jan 13;7(1):129-37. doi: 10.3390/toxins7010129.
• [31] Effects of olanzapine on serum protein phosphorylation patterns in patients with schizophrenia. Proteomics Clin Appl. 2015 Oct;9(9-10):907-16. doi: 10.1002/prca.201400148. Epub 2015 May 15.
• [32] Retinol and retinoic acid bind human serum albumin: stability and structural features. Int J Biol Macromol. 2007 Apr 10;40(5):484-90. doi: 10.1016/j.ijbiomac.2006.11.005. Epub 2006 Nov 24.
• [33] Auto-oxidation of Isoniazid Leads to Isonicotinic-Lysine Adducts on Human Serum Albumin. Chem Res Toxicol. 2015 Jan 20;28(1):51-8. doi: 10.1021/tx500285k. Epub 2014 Dec 9.
• [34] The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999 Oct 8;274(41):29303-10. doi: 10.1074/jbc.274.41.29303.
• [35] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [36] Effect of clofibrate on plasma proteins including components of the hemostatic mechanism. Clin Chim Acta. 1976 Jan 2;66(1):9-17. doi: 10.1016/0009-8981(76)90366-1.
• [37] Use of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates. J Chromatogr A. 2011 Apr 15;1218(15):2072-8. doi: 10.1016/j.chroma.2010.09.070. Epub 2010 Oct 16.
• [38] Serum protein binding of nonsteroidal antiinflammatory drugs: a comparative study. J Pharmacokinet Biopharm. 1997 Feb;25(1):63-77. doi: 10.1023/a:1025719827072.
• [39] Interaction of valproic acid with nonsteroidal antiinflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: lack of interaction in uremic sera due to the presence of endogenous factors. Ther Drug Monit. 1996 Dec;18(6):654-9. doi: 10.1097/00007691-199612000-00005.
• [40] Biological evaluation of cobalt(II) complexes with non-steroidal anti-inflammatory drug naproxen. J Inorg Biochem. 2012 Feb;107(1):54-64. doi: 10.1016/j.jinorgbio.2011.10.014. Epub 2011 Nov 3.
• [41] Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Cancer Chemother Pharmacol. 2000;45(5):417-22. doi: 10.1007/s002800051011.
• [42] Identification of flucloxacillin-modified hepatocellular proteins: implications in flucloxacillin-induced liver injury. Toxicol Sci. 2023 Mar 20;192(1):106-116. doi: 10.1093/toxsci/kfad015.
• [43] A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. J Pharm Biomed Anal. 2010 Jul 8;52(3):420-4. doi: 10.1016/j.jpba.2009.06.023. Epub 2009 Jun 18.
• [44] Regulation of epithelial cell morphology and functions approaching to more in vivo-like by modifying polyethylene glycol on polysulfone membranes. PLoS One. 2012;7(4):e36110.
• [45] Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins. Chem Res Toxicol. 2016 Jan 19;29(1):109-16. doi: 10.1021/acs.chemrestox.5b00460. Epub 2015 Dec 29.
• [46] Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome. Drug Metab Dispos. 2005 Apr;33(4):596-602. doi: 10.1124/dmd.104.002782. Epub 2005 Jan 7.
• [47] Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study. Hypertens Res. 2007 Jun;30(6):529-33. doi: 10.1291/hypres.30.529.
• [48] Chromatographic studies of changes in binding of sulfonylurea drugs to human serum albumin due to glycation and fatty acids. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Nov 15;878(30):3193-7. doi: 10.1016/j.jchromb.2010.09.033. Epub 2010 Oct 23.
• [49] Albumin Protects Lung Cells against Acrolein Cytotoxicity and Acrolein-Adducted Albumin Increases Heme Oxygenase 1 Transcripts. Chem Res Toxicol. 2020 Jul 20;33(7):1969-1979. doi: 10.1021/acs.chemrestox.0c00146. Epub 2020 Jun 29.
• [50] Urea-induced denaturation of human serum albumin labeled with acrylodan. J Protein Chem. 2002 Feb;21(2):75-9. doi: 10.1023/a:1014508610017.
• [51] Albumin, a new biomarker of organophosphorus toxicant exposure, identified by mass spectrometry. Toxicol Sci. 2005 Feb;83(2):303-12. doi: 10.1093/toxsci/kfi023. Epub 2004 Nov 3.
• [52] Comparison of graphical and computerized methods for calculating binding parameters for two strongly bound drugs to human serum albumin. J Pharm Sci. 1976 Aug;65(8):1182-7. doi: 10.1002/jps.2600650813.
• [53] Nickel-quinolones interaction. Part 5-Biological evaluation of nickel(II) complexes with first-, second- and third-generation quinolones. J Inorg Biochem. 2011 Oct;105(10):1273-85. doi: 10.1016/j.jinorgbio.2011.06.005. Epub 2011 Jun 29.
• [54] The common chemical motifs within anesthetic binding sites. Anesth Analg. 2007 Feb;104(2):318-24. doi: 10.1213/01.ane.0000253029.67331.8d.
• [55] Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma. J Pharmacokinet Biopharm. 1994 Feb;22(1):19-40. doi: 10.1007/BF02353408.
• [56] Characterization of the binding of sulfonylurea drugs to HSA by high-performance affinity chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jun 1;878(19):1590-8. doi: 10.1016/j.jchromb.2010.04.019.
• [57] Comparative analysis the binding affinity of mycophenolic sodium and meprednisone with human serum albumin: Insight by NMR relaxation data and docking simulation. Chem Biol Interact. 2016 Mar 25;248:52-9. doi: 10.1016/j.cbi.2016.02.009. Epub 2016 Feb 16.
• [58] Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J Control Release. 2010 Mar 3;142(2):206-13. doi: 10.1016/j.jconrel.2009.10.025. Epub 2009 Nov 10.
• [59] Supplementation with Alfacalcidol increases protein intake and serum albumin concentration in patients undergoing hemodialysis with hpoalbumineamia. Blood Purif. 2004;22(2):210-5. doi: 10.1159/000076855.
• [60] Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug Chem. 2007 May-Jun;18(3):702-16. doi: 10.1021/bc0602735. Epub 2007 Mar 23.
• [61] Discontinuous drug binding to proteins: binding of an antineoplastic benzyl styryl sulfone to albumin and enzymes in vitro and in phase I clinical trials. Drug Metab Dispos. 2010 Sep;38(9):1480-5. doi: 10.1124/dmd.110.033001. Epub 2010 May 25.
• [62] Binding of alkyl- and alkoxy-substituted simple phenolic compounds to human serum proteins. Res Commun Mol Pathol Pharmacol. 2000;107(1-2):167-73.
• [63] Effect of telmisartan on ambulatory blood pressure monitoring, plasma brain natriuretic peptide, and oxidative status of serum albumin in hemodialysis patients. Hypertens Res. 2005 Dec;28(12):987-94. doi: 10.1291/hypres.28.987.
• [64] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [65] Interactions of human serum albumin with retinoic acid, retinal and retinyl acetate. Biochem Pharmacol. 2007 Mar 15;73(6):901-10. doi: 10.1016/j.bcp.2006.11.023. Epub 2006 Dec 2.
• [66] Determination of Protein Haptenation by Chemical Sensitizers Within the Complexity of the Human Skin Proteome. Toxicol Sci. 2018 Apr 1;162(2):429-438. doi: 10.1093/toxsci/kfx265.
• [67] Atrazine represses S100A4 gene expression and TPA-induced motility in HepG2 cells. Toxicol In Vitro. 2014 Mar;28(2):156-63. doi: 10.1016/j.tiv.2013.10.019. Epub 2013 Nov 6.
• [68] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [69] Influence of uremia, hemodialysis, and nonesterified fatty acids on zomepirac plasma protein binding. Clin Pharmacol Ther. 1983 Nov;34(5):681-8. doi: 10.1038/clpt.1983.232.
• [70] Comprehensive analysis of transcriptomic changes induced by low and high doses of bisphenol A in HepG2 spheroids in vitro and rat liver in vivo. Environ Res. 2019 Jun;173:124-134. doi: 10.1016/j.envres.2019.03.035. Epub 2019 Mar 18.
• [71] In vitro study on the binding of herbicide glyphosate to human serum albumin by optical spectroscopy and molecular modeling. J Photochem Photobiol B. 2008 Jan 30;90(1):26-32. doi: 10.1016/j.jphotobiol.2007.10.003. Epub 2007 Oct 18.
• [72] Chronic high glucose inhibits albumin reabsorption by lysosomal alkalinization in cultured porcine proximal tubular epithelial cells (LLC-PK1). Diabetes Res Clin Pract. 2006 Jun;72(3):223-30. doi: 10.1016/j.diabres.2005.10.019. Epub 2005 Nov 28.
• [73] Novel Transgenic Mouse Model for Studying Human Serum Albumin as a Biomarker of Carcinogenic Exposure. Chem Res Toxicol. 2016 May 16;29(5):797-809. doi: 10.1021/acs.chemrestox.5b00529. Epub 2016 Apr 14.
• [74] Ellagic acid mitigates SNO-PDI induced aggregation of Parkinsonian biomarkers. ACS Chem Neurosci. 2014 Dec 17;5(12):1209-20. doi: 10.1021/cn500214k. Epub 2014 Oct 8.
• [75] Quercetin ameliorate insulin resistance and up-regulates cellular antioxidants during oleic acid induced hepatic steatosis in HepG2 cells. Toxicol In Vitro. 2013 Mar;27(2):945-53.
• [76] Fatty acids binding to human serum albumin: Changes of reactivity and glycation level of Cysteine-34 free thiol group with methylglyoxal. Chem Biol Interact. 2014 Dec 5;224:42-50. doi: 10.1016/j.cbi.2014.10.008. Epub 2014 Oct 17.
• [77] Characterization of the mangiferin-human serum albumin complex by spectroscopic and molecular modeling approaches. J Pharm Biomed Anal. 2009 Apr 5;49(3):753-9. doi: 10.1016/j.jpba.2008.12.017. Epub 2008 Dec 24.
• [78] Protein overload-induced NF-kappaB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependent pathway. J Am Soc Nephrol. 2002 May;13(5):1179-89.
• [79] Stopped-flow kinetic studies of the interaction of bovine folate binding protein (FBP) and folate. Biosci Rep. 2006 Aug;26(4):291-9. doi: 10.1007/s10540-006-9023-y.
• [80] Aluminium-induced impairment of Ca2+ modulatory action on GABA transport in brain cortex nerve terminals. J Inorg Biochem. 2003 Sep 15;97(1):132-42. doi: 10.1016/s0162-0134(03)00256-3.
• [81] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [82] Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation. J Pharm Sci. 2008 Dec;97(12):5147-57. doi: 10.1002/jps.21394.
• [83] Benoxaprofen photosensitization of cell membrane disruption. J Invest Dermatol. 1984 Mar;82(3):214-8. doi: 10.1111/1523-1747.ep12260034.
• [84] Fate of the teratogenic and carcinogenic ochratoxin A in human perfused placenta. Toxicol Lett. 2012 Jan 5;208(1):92-9. doi: 10.1016/j.toxlet.2011.10.013. Epub 2011 Oct 20.
• [85] Folic acid alleviates jaundice of phenylhydrazine (PHA)-induced neonatal rats by reducing Lys-homocysteinylation of albumin. Cell Biol Toxicol. 2021 Oct;37(5):679-693. doi: 10.1007/s10565-021-09602-3. Epub 2021 Mar 31.
• [86] Serum albumins and detoxication of anti-cholinesterase agents. Chem Biol Interact. 2010 Sep 6;187(1-3):325-9. doi: 10.1016/j.cbi.2010.03.001. Epub 2010 Mar 6.
• [87] A new assay for albumin and hemoglobin adducts of 1,2- and 1,4-benzoquinones. Chem Biol Interact. 1998 Sep 4;115(2):117-39. doi: 10.1016/s0009-2797(98)00067-2.
• [88] Thermodynamics of benzoquinone-induced conformational changes in nucleic acids and human serum albumin. Chem Biol Interact. 2023 Jan 5;369:110281. doi: 10.1016/j.cbi.2022.110281. Epub 2022 Nov 25.